Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Background This study evaluated the safety, tolerability, pharmacokinetics, immunogenicity and antitumor activity of single and multiple doses of nivolumab in Japanese patients with malignant solid tumors. Subjects and Methods This was an open-label, dose-escalation study in 17 patients with advance...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Yamamoto, Noboru, Nokihara, Hiroshi, Yamada, Yasuhide, Shibata, Takashi, Tamura, Yosuke, Seki, Yoshitaka, Honda, Kazunori, Tanabe, Yuko, Wakui, Hiroshi, Tamura, Tomohide
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer US 2016
Aiheet:
Phase I Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352798/
https://ncbi.nlm.nih.gov/pubmed/27928714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0411-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia